Further synthetic and biological studies on vitamin D hormone antagonists based on C24-alkylation and C2α-functionalization of 25-dehydro-1α- hydroxyvitamin D3-26,23-lactones

Journal of Medicinal Chemistry

Volumn 49, Issue 24, 2006, Pages 7063-7075

  Saito, Nozomi ^a   Matsunaga, Toshihiro ^a   Saito, Hiroshi ^b   Anzai, Miyuki ^b   Takenouchi, Kazuya ^b   Miura, Daishiro ^b   Namekawa, Jun Ichi ^b   Ishizuka, Seiichi ^b   Kittaka, Atsushi ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b TEIJIN LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 DEHYDRO 1ALPHA HYDROXY 24 ISOBUTYLVITAMIN D3 26,23 LACTONE; 25 DEHYDRO 1ALPHA HYDROXY 24 METHYLVITAMIN D3 26,23 LACTONE; 25 DEHYDRO 1ALPHA HYDROXY 24 PROPYLVITAMIN D3 26,23 LACTONE; 25 DEHYDRO 24 BUTYL 1ALPHA HYDROXYVITAMIN D3 26,23 LACTONE; 25 DEHYDRO 24 ETHYL 1ALPHA HYDROXYVITAMIN D3 26,23 LACTONE; CALCITRIOL; HORMONE ANTAGONIST; TEI 9647; TEI 9648;

ALKYLATION; ALLYLATION; ARTICLE; BINDING AFFINITY; CATALYSIS; CELL DIFFERENTIATION; CELL STRAIN HL 60; CYCLIZATION; DIASTEREOISOMER; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; LACTONIZATION; NONHUMAN; STEREOCHEMISTRY;

ALKYLATION; ANIMALS; CALCITRIOL; CATALYSIS; CELL DIFFERENTIATION; CHICKENS; CHOLECALCIFEROL; CHROMIUM; CYCLIZATION; HL-60 CELLS; HUMANS; LACTONES; PALLADIUM; RECEPTORS, CALCITRIOL; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845370888     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060797q     Document Type: Article

References (68)

1. nd Edition, Feldman, D., Glorieux, F. H., Pike, J. W., Eds.; Academic Press: New York, 2005.
2. (b) Ettinger, R. A.; DeLuca, H. F. The Vitamin D Endocrine System and Its Therapeutic Potential. Adv. Drug Res. 1996, 28, 269-312.
3. Bouillon, R.; Okamura, W. H.; Norman, A. W. Structure-Function Relationships in the Vitamin D Endocrine System. Endocr. Rev. 1995, 16, 200-257.
4. (a) Evans, R. M. The Steroid and Thyroid Hormone Receptor Superfamily. Science 1988, 240, 889-895.
5. 3 Receptors. Cell 1991, 65, 1255-1266.
6. (c) Chambon, P. The Nuclear Receptor Superfamily: A Personal Retrospect on the First Two Decades. Mol. Endocrinol. 2005, 19, 1418-1428.
7. Takeyama, K.; Masuhiro, Y.; Fuse, H.; Endoh, H.; Murayama, A.; Kitanaka, S.; Suzawa, M.; Yanagisawa, J.; Kato, S. Selective Interaction of Vitamin D Receptor with Transcriptional Coactivators by a Vitamin D Analog. Mol. Cell Biol. 1999, 19, 1049-1055.
8. 3. J. Med. Chem. 2002, 45, 1825-1834.
9. For a recent review on the function of VDR in response to 1 and the other synthetic ligands, see: Carlberg, C. Current Understanding of the Function of the Nuclear Vitamin D Receptor in Response to Its Natural and Synthetic Ligands. In Vitamin D Analogs in Cancer Prevention and Therapy, Recent Results in Cancer Research. 164; Reichrath, J., Friedrich, M., Tilgen, M., Eds.; Springer: Berlin, 2003; pp 29-42.
10. Carlberg, C. Ligand-Mediated Conformational Changes of the VDR are Required for Gene Transactivation. J. Steroid Biochem. Mol. Biol. 2004, 89-90, 227-232.
11. For selected papers on the synthesis of vitamin D analogs, see: (a) Uskokovic, M. R., Eds. Bioorg. Med. Chem. Lett; Symposia-in-Print 1993, 3, 1777-1896.
12. (b) Jones, G.; Calverley, M. J. A Dialogue on Analogues Newer Vitamin-D Drugs for Use in Bone Disease, Psoriasis, and Cancer. Trends Endocrinol. Metab. 1993, 4, 297-303.
13. (c) Zhu, G. D.; Okamura, W. H. Synthesis of Vitamin D (Calciferol). Chem. Rev. 1995, 95, 1877-1952.
14. 3. Bioorg. Med. Chem. Lett. 1998, 8, 151-156.
15. 3 and Their 20-Epimers: Unique Activity Profiles Depending on the Stereochemistry of the A-Ring and at C-20. J. Med. Chem. 2000, 43, 4247-4265.
16. 3 Analogues. Bioorg. Med. Chem. Lett. 2000, 10, 1129-1132.
17. 3 Analogues and Their Docking to Vitamin D Receptor. J. Org. Chem. 2001, 66, 8760-8771.
18. 3: Remarkably High Affinity to Vitamin D Receptor. Org. Lett. 2000, 2, 2619-2622.
19. 3 Analogues Including 2-epi-ED-71 and Their 20-Epimers with HL-60 Cell Differentiation Activity. J. Org. Chem. 2004, 69, 7463-7471.
20. 3 Analogs. Vitamin D Analogs in Cancer Prevention and Therapy, Recent Results in Cancer Research. 164; Reichrath, J.; Friedrich, M.; Tilgen, W., Eds.; Springer-Verlag: Berlin, Heidelberg, 2003; pp 289-317.
21. 3 Analogues. Synlett 2003, 1175-1179.
22. 3 with Julia Olefination: High Potency in Induction of Differentiation on HL-60 Cells. J. Org. Chem. 2003, 68, 7407-7415.
23. 3 Analogs of an Osteoporosis Drug. J. Org. Chem. 1994, 59, 7855-7861.
24. 3. Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing. J. Org. Chem. 1995, 60, 4617-4628.
25. Rochel, N.; Wurtz, J. M.; Mitschler, A.; Klaholz, B.; Moras, D. The Crystal Structure of the Nuclear Receptor for Vitamin D Bound to Its Natural Ligand. Mol. Cell 2000, 5, 173-179.
26. 3 and their 20-Epimers: Possible Binding Modes of Potent A-Ring Analogues to Vitamin D Receptor. Chem. Biol. 2001, 8, 1011-1024. See also refs 10b and 11.
27. 3. Biochemistry 1984, 23, 1473-1478.
28. 3 under Physiological Conditions. Vitamin D: Molecular, Cellular and Clinical Endocrinology; Norman, A. W., Schaefer, K., Grigoleit, H. G., von Herrath, D., Eds.; Walter de Gruyter: Berlin, 1988; pp 143-144.
29. 3. J. Biol. Chem. 1999, 274, 16392-16399.
30. 3 Analogue toward Vitamin D Receptor Function. J. Biol. Chem. 1999, 274, 32376-32381.
31. 3-26,23-lactone Analogs Antagonize Differentiation of Human Leukemia Cells (HL-60 cells) but not of Human Acute Promyelocytic Leukemia Cells (NB4 cells). FEBS Lett. 1999, 460, 297-302.
32. 3 in Human Promyelocytic Leukemia (HL-60) Cells. Arch. Biochem. Biophys. 2000, 380, 92-102.
33. 3. Endocrinology 2001, 142, 59-67.
34. 3. Steroids 2001, 66, 227-237.
35. 3 Is Mediated by a Lack of Ligand-induced Vitamin D Receptor Interaction with Coactivators. J. Biol. Chem. 2000, 275, 16506-16512.
36. 3 Receptor. Mol. Pharmacol. 2000, 58, 1067-1074.
37. 3 Show Cell-Specific Actions. Chem. Biol. 2000, 7, 885-894.
38. 3 Receptor for the Partial Agonism of Carboxylic Ester Antagonists. J. Mol. Biol. 2002, 315, 229-238.
39. 3 Antagonist. Bioorg. Med. Chem. Lett. 2004, 14, 2579-2583.
40. 3-26,23-lactams. Designed on the Basis of the Helix 12-Folding Inhibition Hypothesis. J. Med. Chem. 2006, 49, 2398-2406.
41. (a) Carlberg, C. Molecular Basis of the Selective Activity of Vitamin D Analogues. J. Cell. Biochem. 2003, 88, 274-281.
42. 3 Receptor Antagonists. Mol. Pharmacol. 2001, 59, 1478-1485.
43. Recent reports on Paget's bone disease, see: (a) Reddy, S. V.; Kurihara, N.; Menaa, C.; Roodman, G. D. Paget's Disease of Bone: a Disease of the Osteoclast. Rev. Endocr. Metab. Disord. 2001, 2, 195-201.
44. (b) Reddy, S. V. Etiology of Paget's Disease and Osteoclast Abnormalities. J. Cell. Biochem. 2004, 93, 688-696.
45. (c) Roodman, G. D.; Windle, J. J. Paget Disease of Bone. J. Clin. Invest. 2005, 115, 200-208.
46. 3 from Pagetic Bone Marrow Cells. J. Steroid Biochem. Mol. Biol. 2004, 89-90, 331-334.
47. 3-26,23- lactone, a Vitamin D Receptor Antagonist that Inhibits Osteoclast Formation and Bone Resorption in Bone Marrow Cultures from Patients with Paget's Disease. Endocrinology 2005, 146, 2023-2030.
48. 3-26,23-lactones. Org. Biomol. Chem. 2003, 1, 4396-4402.
49. 3-26,23-lactones and Their 2α-Functionalized Analogues as Highly Potent VDR Antagonists. Tetrahedron 2004, 60, 7951-7961.
50. 3 Lactones Using Ruthenium-Catalyzed Intermolecular Enyne Metathesis: Potent Vitamin D Receptor Antagonists. Synthesis 2005, 2533-2543.
51. Introduction of the C2α methyl group into the other type of vitamin D antagonist ZK159222 was also reported by our group. Fujishima, T.; Kojima, Y.; Azumaya, I.; Kittaka, A.; Takayama, H. Design and Synthesis of Potent Vitamin D Receptor Antagonists with A-Ring Modifications: Remarkable Effects of 2α-Methyl Introduction on Antagonistic Activity. Bioorg. Med. Chem. 2003, 11, 3621-3631.
52. 3-26,23-lactones. Org. Lett. 2003, 5, 4859-4862.
53. Trost, B. M.; Dumas, J.; Villa, M. New Strategies for the Synthesis of Vitamin D Metabolites via Pd-Catalyzed Reactions. J. Am. Chem. Soc. 1992, 114, 9836-9845.
54. Okuda, Y.; Nakatsukasa, S.; Oshima, K.; Nozaki, H. A Facile and Stereoselective Synthesis of α-Methylene-γ-butyrolactone by Means of Chromium(II) Reagent. Chem. Lett. 1985, 481-484.
55. Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. High-field FT NMR Application of Mosher's Method. The Absolute Configurations of Marine Terpenoids. J. Am. Chem. Soc. 1991, 113, 4092-4096.
56. (a) Eisman, J. A.; Hamstra, A. J.; Kream, B. E.; DeLuca, H. F. A Sensitive, Precise, and Convenient Method for Determination of 1,25-Dihydroxyvitamin D in Human Plasma. Arch. Biochem. Biophys. 1976, 176, 235-243.
57. 3 Receptor in the Human Leukemia Cell Line, HL-60, with Diisopropylfluorophosphate. Biochim. Biophys. Acta 1989, 1010, 20-27.
58. Collins, S. J.; Ruscetti, F. W.; Gallagher, R. E.; Gallo, R. C. Normal Functional Characteristics of Cultured Human Promyelocytic Leukemia Cells (HL-60) After Induction of Differentiation by Dimethylsulfoxide. J. Exp. Med. 1979, 149, 969-974.
59. 3 Analogues with a Double Side Chain: Marked Cell Differentiation Activity. Bioorg. Med. Chem. Lett. 2002, 12, 3255-3258.
60. 3 Analogues Utilizing Grignard Reaction towards Methyl 2,3-Anhydro-4,6-O- benzylidene-α-D-mannopyranoside. Heterocycles 2003, 61, 327-338.
61. 3. Bioorg. Med. Chem. Lett. 2003, 13, 3503-3506.
62. 3-26,23S-lactone Antagonizes the Nuclear Vitamin D Receptor by Mediating a Unique Noncovalent Conformational Change. Mol. Endocrinol. 2000, 14, 1788-1796.
63. (a) Ochiai, E.; Miura, D.; Eguchi, H.; Takenouchi, K.; Harada, Y.; Azuma, Y.; Kamimura, T.; Ishizuka, S. Antagonistic Actions of TEI-9647 Depend on the Primary Structure of AF-2 Domain of Vitamin D Receptors. J. Bone Miner. Res. 2003, 18 (suppl. 2), SI03.
64. 3-26,23-lactone Depends on the Primary Structure of the Carboxyl-Terminal Region of the Vitamin D Receptor. Mol. Endocrinol. 2005, 19, 1147-1157.
65. (c) Peräkylä, M.; Molnár, F.; Carlberg, C. A Structural Basis for the Species-Specific Antagonism of 26,23-Lactones on Vitamin D Signaling. Chem. Biol. 2004, 11, 1147-1156.
66. 3 Antagonists. J. Steroid Biochem. Mol. Biol. 2004, 89-90, 31-34.
67. Some biologically active natural products having an α-methylene- γ-lactone structure react with the thiol group of cysteine to give the corresponding cysteine adduct: Kupchan, S. M.; Fessler, D. C.; Eakin, M. A.; Giacobbe, T. J. Reactions of Alpha Methylene Lactone Tumor Inhibitors with Model Biological Nucleophile. Science 1970, 168, 376-377.
68. Recently, X-ray crystallographic analyses of VDR-(1a-c) complexes were reported, see: Hourai, S.; Fujishima, T.; Kittaka, A.; Suhara, Y.; Takayama, H.; Rochel, N.; Moras, D. Probing a Water Channel near the A-Ring of Receptor-Bound 1α,25-Dihydroxyvitamin D3 with Selected 2α-Substituted Analogues. J. Med. Chem. 2006, 49, 5199-5205.